BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

150 related articles for article (PubMed ID: 3845792)

  • 1. In vitro activity of Sch 34343 against enterococci and other gram-positive bacteria.
    Eliopoulos GM; Reiszner E; Moellering RC
    Antimicrob Agents Chemother; 1985 Jan; 27(1):28-32. PubMed ID: 3845792
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Comparative activity of the penem antibiotic Sch 34343 against gram-negative and gram-positive bacteria with special reference to multiresistant strains.
    Kayser FH; Novak J; Strässle A
    J Antimicrob Chemother; 1985 Jun; 15 Suppl C():137-46. PubMed ID: 3849537
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Antistreptococcal activity of Sch 34343, a new penem antibiotic.
    Yu PK; Washington JA
    J Antimicrob Chemother; 1985 Jun; 15 Suppl C():67-71. PubMed ID: 3928578
    [TBL] [Abstract][Full Text] [Related]  

  • 4. In vitro activity of SCH-34343, a new penam, and other antimicrobial agents against clinical isolates from cancer patients.
    Rolston KV; Alvarez ME; Hoy JF; Alderman HC; Ho DH; Bodey GP
    Chemotherapy; 1986; 32(6):506-14. PubMed ID: 3100147
    [TBL] [Abstract][Full Text] [Related]  

  • 5. In-vitro activity of Sch 34343, a new penam, against gram-positive isolates from cancer patients.
    Rolston KV; Alvarez ME; Hoy JF; Alderman HC; Ho DH; Bodey GP
    J Antimicrob Chemother; 1986 Aug; 18(2):159-62. PubMed ID: 3093447
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Comparative in vitro activity of CGP 31608, a new penem antibiotic.
    Eliopoulos GM; Wennersten C; Reiszner E; Moellering RC
    Antimicrob Agents Chemother; 1987 Aug; 31(8):1188-93. PubMed ID: 3498437
    [TBL] [Abstract][Full Text] [Related]  

  • 7. In vitro activity and beta-lactamase stability of a new penem, CGP 31608.
    Neu HC; Chin NX; Neu NM
    Antimicrob Agents Chemother; 1987 Apr; 31(4):558-69. PubMed ID: 3496845
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Comparative antimicrobial activity of gatifloxacin with ciprofloxacin and beta-lactams against gram-positive bacteria.
    Bassetti M; Dembry LM; Farrel PA; Callan DA; Andriole VT
    Diagn Microbiol Infect Dis; 2001 Nov; 41(3):143-8. PubMed ID: 11750168
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Comparative in-vitro activity of LY146032 and eight other antibiotics against gram-positive bacteria isolated from children.
    Kline MW; Mason EO; Kaplan SL; Lamberth LB; Johnson GS
    J Antimicrob Chemother; 1987 Aug; 20(2):203-7. PubMed ID: 2822647
    [TBL] [Abstract][Full Text] [Related]  

  • 10. In vitro activities of two ketolides, HMR 3647 and HMR 3004, against gram-positive bacteria.
    Malathum K; Coque TM; Singh KV; Murray BE
    Antimicrob Agents Chemother; 1999 Apr; 43(4):930-6. PubMed ID: 10103202
    [TBL] [Abstract][Full Text] [Related]  

  • 11. In vitro activities of RWJ-54428 (MC-02,479) against multiresistant gram-positive bacteria.
    Chamberland S; Blais J; Hoang M; Dinh C; Cotter D; Bond E; Gannon C; Park C; Malouin F; Dudley MN
    Antimicrob Agents Chemother; 2001 May; 45(5):1422-30. PubMed ID: 11302805
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Evaluation of the in-vitro antibacterial activity of Sch 34343.
    Adam C; Naples L; Weiss W; Sabatelli F; Hare R; Loebenberg D; Miller GH
    J Antimicrob Chemother; 1985 Jun; 15 Suppl C():39-56. PubMed ID: 3875604
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Antimicrobial effects of the combination of ceftibuten and an orally absorbed penem SCH 29482.
    Chin NX; Gu JW; Neu HC
    Diagn Microbiol Infect Dis; 1991; 14(1):79-83. PubMed ID: 2013213
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Comparative in-vitro activity of Sch 34343, imipenem, cefpirome and cefotaxime.
    Bauernfeind A
    J Antimicrob Chemother; 1985 Jun; 15 Suppl C():155-64. PubMed ID: 3897170
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Comparative in-vitro activity of Sch 34343, a new penem antibiotic.
    Reeves DS; Holt HA; Bywater MJ
    J Antimicrob Chemother; 1985 Jun; 15 Suppl C():57-66. PubMed ID: 3849538
    [TBL] [Abstract][Full Text] [Related]  

  • 16. European Glycopeptide Susceptibility Survey of gram-positive bacteria for 1995. European Glycopeptide Resistance Survey Study Group.
    Felmingham D; Brown DF; Soussy CJ
    Diagn Microbiol Infect Dis; 1998 Aug; 31(4):563-71. PubMed ID: 9764397
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Comparative activity of CGP 31608, nafcillin, cefamandole, imipenem, and vancomycin against methicillin-susceptible and methicillin-resistant staphylococci.
    Sachdeva M; Hackbarth C; Stella FB; Chambers HF
    Antimicrob Agents Chemother; 1987 Oct; 31(10):1549-52. PubMed ID: 3481245
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Bactericidal activity and killing rate of serum against gram-positive cocci in volunteers receiving imipenem, oxacillin, vancomycin or ampicillin plus gentamicin.
    Van der Auwera P; Van Laethem Y; Klastersky J
    J Antimicrob Chemother; 1987 Aug; 20(2):239-49. PubMed ID: 3478329
    [TBL] [Abstract][Full Text] [Related]  

  • 19. In vitro activity of LY146032 (daptomycin) against selected aerobic bacteria.
    Jorgensen JH; Maher LA; Redding JS
    Eur J Clin Microbiol; 1987 Feb; 6(1):91-6. PubMed ID: 3032612
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Review of the in vitro spectrum of activity of imipenem.
    Jones RN
    Am J Med; 1985 Jun; 78(6A):22-32. PubMed ID: 3890537
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.